Advanced Search

Journal of Traditional Chinese Medicine >

2025 , Vol. 45 >Issue 4: 836 - 844

DOI: https://doi.org/10.19852/j.cnki.jtcm.2025.04.012

Original Articles

Clinical study of Yiqi Liangxue Shengji prescription (益气凉血生肌方) for improving cardiac function after myocardial ischemia reperfusion injury in patients with acute myocardial infarction: a randomized, double-blind, placebo-controlled trial

  • Yuxuan LI ,
  • Yan LI ,
  • Wujiao WANG ,
  • Xiaoyun CUI ,
  • Jie WAN ,
  • Kun ZHOU ,
  • Jinjin LU ,
  • Jing LIU ,
  • Qian LIN ,
  • Dong LI
Expand
  • 1 Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
    2 Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
Associate Chief Physician LI Dong, Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China. dongdong871103@163.com,Telephone: +86-13910565673; +86-15201489469
Prof. LIN Qian, Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China. linqian62@126.com;
First author contact:

LI Yuxuan and LI Yan are co-first authors and contributed equally to this work

Received date: 2024-09-22

  Accepted date: 2025-01-23

  Online published: 2025-07-25

Supported by

Capital’s Funds for Health Improvement and Research: Clinical Study on Yiqi Liangxue Shengji Prescription for Improving Cardiac Function after Myocardial Ischemia Reperfusion Injury in Patients with Acute Myocardial Infarction(CFH 2020-4-4204);Beijing University of Traditional Chinese Medicine Qihuang Yingcai?Excellent Young Science and Technology Talent Cultivation Program(K2023A03);Beijing University of Traditional Chinese Medicine Dongfang Hospital High-level Capacity Building Project "Zhuoyuan" Project National Talent Precision Cultivation Program(DFRCZY-2024GJRC012)

Fold

Abstract

OBJECTIVE: To evaluate the effect of Yiqi Liangxue Shengji prescription (益气凉血生肌方, YQLXSJ) on cardiac function and outcomes in acute myocardial infarction (AMI) patients with myocardial ischemia-reperfusion injury (MIRI) and to determine its clinical efficacy.

METHODS: This prospective, randomized, double-blind, placebo-controlled trial enrolled hospitalized patients with AMI who underwent percutaneous coronary intervention and experienced MIRI either intraoperatively or postoperatively. Participants were randomly allocated to the treatment group, which received YQLXSJ, or the control group, which received a placebo, concurrent with standard Western Medicine therapy. The intervention period lasted 8 weeks. The primary outcome measure was left ventricular ejection fraction (LVEF), determined by echocardiography. Secondary outcomes included N-terminal pro brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) levels, left ventricular internal diameter, major adverse cardiovascular events (MACE), angina pectoris scores, and Chinese medicine evidence scores.

RESULTS: Following 8 weeks of intervention, the treatment group demonstrated a significant increase in LVEF and a marked reduction in NT-proBNP when compared to the control group. There was also a significant decrease in peak cTnI levels, Chinese medicine evidence scores, and angina pectoris scores. The control group’s left ventricular end-systolic diameter (LVESD) significantly increased compared to baseline after 8 weeks (P < 0.05), whereas the treatment group's LVESD showed no significant change from baseline (P > 0.05). Although the treatment group showed a downward trend in MACE incidence compared to the control group, this difference was not statistically significant (P > 0.05).

CONCLUSIONS: This study demonstrated that the addition of YQLXSJ to standard therapy can improve cardiac function and alleviate clinical symptoms in AMI patients with MIRI, and also showed a potential to mitigate the incidence of MACE. Furthermore, YQLXSJ displayed a favorable safety profile in clinical application.

Key words： myocardial reperfusion injury; stroke volume; natriuretic peptide, brain; troponin I; randomized controlled trial; blind; Yiqi Liangxue Shengji prescription

Cite this article

Yuxuan LI , Yan LI , Wujiao WANG , Xiaoyun CUI , Jie WAN , Kun ZHOU , Jinjin LU , Jing LIU , Qian LIN , Dong LI . Clinical study of Yiqi Liangxue Shengji prescription (益气凉血生肌方) for improving cardiac function after myocardial ischemia reperfusion injury in patients with acute myocardial infarction: a randomized, double-blind, placebo-controlled trial[J]. Journal of Traditional Chinese Medicine, 2025 , 45(4) : 836 -844 . DOI: 10.19852/j.cnki.jtcm.2025.04.012

References

1. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013; 123: 92-100.
2. Hausenloy DJ, Botker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 2017; 38: 935-41.
3. Wohlfahrt P, Jen?a D, Stehlik J, et al. Heart failure-related quality-of-life impairment after myocardial infarction. Clin Res Cardiol 2023; 112: 39-48.
4. Ibá?ez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015; 65: 1454-71.
5. Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur Heart J 2015; 36: 377-84.
6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119-31.
7. Kloner RA, Hale SL, Dai W, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Assoc 2012; 1: e001644.
8. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J 2016; 37: 1296-303.
9. Siddiqi N, Neil C, Bruce M, et al. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur Heart J 2014; 35: 1255-62.
10. B?tker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375: 727-34.
11. Hausenloy DJ, Kharbanda RK, M?ller UK, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet 2019; 394: 1415-24.
12. Kapur NK, Alkhouli MA, DeMartini TJ, et al. Unloading the left ventricle before reperfusion in patients with anterior ST-segment-elevation myocardial infarction. Circulation 2019; 139: 337-46.
13. Ma Z, Long J, Jia W, et al. Randomize-controlled trial of Yiqi Liangxue Shengji formula in preventing major adverse cardiovascular events after percutaneous coronary intervention for coronary heart disease. Zhong Yi Za Zhi 2019; 60: 1837-42.
14. Jia W, Wan J, Ma Z, et al. Influences of Yiqi Liangxue Shengji prescription on quality of life in patients after PCI. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2019; 17: 3282-4.
15. Jia W, Wan J, Ma Z, et al. Effects of Yiqi Liangxue Shengji prescription on TCM symptoms and syndrome elements after PCI. Shi Jie Zhong Xi Yi Jie He Za Zhi 2021; 16: 229-32.
16. Li Y, Yan R, Li P, et al. Experience of Professor Lin Qian in treating perioperative patients with acute myocardial infarction. Zhong Guo Yi Yao Dao Bao 2022; 19: 117-21.
17. Association CSoCoCM, Cardiology EBoCJo. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Zhong Hua Xin Xue Guan Bing Za Zhi 2019: 766-83.
18. Association CSoCoCM, Cardiology EBoCJo. Guideline and consensus for the management of patients with non-ST-elevation acute coronary syndrome (2016). Zhong Hua Xin Xue Guan Bing Za Zhi 2017: 359-76.
19. Liu H, Wu Y, Wang X, et al. Percutaneous coronary intervention (PCI) Perioperative myocardial injury: expert consensus on diagnosis and treatment in Traditional Chinese Medicine. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2017; 37: 389-93.
20. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-69.
21. Mao T, Xie L, Guo Y, et al. Mechanistic exploration of Yiqi Liangxue Shengji prescription on restenosis after balloon injury by integrating metabolomics with network pharmacology. Pharm Biol 2023; 61: 1260-73.
22. You S, Yang Y, Chen K, et al. The protectiv eeffects of Tong-xin-luo on myocardium and microvasculature after reperfusion in acute myocardial infarction. Zhong Hua Xin Xue Guan Bing Za Zhi 2005: 433-7.
23. Wang R. Methods of sample size estimation in randomized controlled clinical trial design. Shanghai Yi Yao 2023; 44: 48-52.
24. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.
25. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008; 117: 1037-44.
26. L?nborg J, Engstr?m T, Ahtarovski KA, et al. Myocardial damage in patients with deferred stenting after STEMI: a DANAMI-3-DEFER substudy. J Am Coll Cardiol 2017; 69: 2794-804.
27. Heusch G, B?tker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol 2015; 65: 177-95.
28. Xie L, Liu Y, Zhou K, Wu Y. Superficial view on TCM pathogenesis of myocardial ischemia reperfusion injury. Zhong Hua Zhong Yi Yao Za Zhi 2015; 30: 3139-41.
29. Chen M, Wang R, Liao L, et al. DanShen Decoction targets miR-93-5p to provide protection against MI/RI by regulating the TXNIP/NLRP3/caspase-1 signaling pathway. Phytomedicine 2024; 135: 156225.
30. Wu N, Chi J, Cai H, et al. Traditional Chinese medication Qili Qiangxin capsule protects against myocardial ischemia-reperfusion injury through suppressing autophagy via the phosphoinositide 3-kinase/protein kinase B/forkhead box O 3 axis. J Ethnopharmacol 2025; 337: 118821.
31. Wang W, Liu L, Long J, et al. Protective effect of Yiqi Liangxue Shengji decoction on hypoxia/reoxygenation injury in human umbilical vein endothelial cells based on mTOR1 signaling pathway. Xian Dai Zhong Xi Yi Jie He Za Zhi 2023; 32: 10-4+37.
32. Liu H, Huang Y, Jin G, et al. Yiqi Liangxue-shengji decoction ameliorates endothelial cell inflammatory response by inhibiting NF-κB pathway. Huan Qiu Zhong Yi Yao 2022; 15: 996-1001.
33. Li Y, Huang Y, Jin G, et al. Research on Yiqi Liangxue Shengji decoction attenuating endothelial cell inflammatory injury based on TLR4/NF-κB pathway. Xian Dai Zhong Xi Yi Jie He Za Zhi 2022; 31: 882-7.
Options
Outlines

/

〈 〉